Halozyme Therapeutics | HALO - Equity Capital And Reserves


Halozyme Therapeutics reported $48.81M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amarin USD 458.89M 6.03M Sep/2025
Amgen USD 8.66B 961M Dec/2025
Baxter International USD 6.13B 1.11B Dec/2025
Cara Therapeutics USD 32.93M 41M Jun/2025
Cytokinetics USD -659.62M 138.5M Dec/2025
DBV Technologies USD 52.85M 33.37M Sep/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Intrexon USD 43.17M 75.33M Jun/2024
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
MannKind USD -51.02M 6.47M Dec/2025
Minerva Neurosciences USD -34.58M 2.47M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
United Therapeutics USD 7.1B 506M Dec/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025